Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TENX | US
0.07
0.52%
Healthcare
Biotechnology
30/06/2024
13/04/2026
14.50
14.38
14.59
14.23
Tenax Therapeutics Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV) TNX-102 and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib) a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics Inc. and changed its name to Tenax Therapeutics Inc. in September 2014. Tenax Therapeutics Inc. was founded in 1967 and is based in Chapel Hill North Carolina.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
91.8%1 month
85.3%3 months
106.2%6 months
88.5%-
0.30
1.50
0.03
0.03
-0.14
-
-
-13.03M
49.43M
49.43M
-
-
-
-
-113.79
0.95
1.13
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.34
Range1M
3.73
Range3M
8.01
Rel. volume
0.50
Price X volume
3.18M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 1.02 | 54.03M | -2.86% | n/a | 35.68% |
| TPST | TPST | Biotechnology | 2.14 | 53.94M | 4.39% | n/a | 119.58% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.257 | 53.51M | 2.31% | n/a | 122.82% |
| OKYO Pharma Limited | OKYO | Biotechnology | 1.53 | 51.77M | 1.32% | n/a | -107.88% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 6.48 | 51.59M | 6.06% | n/a | -6472.02% |
| Akari Therapeutics Plc | AKTX | Biotechnology | 4.2475 | 51.58M | 10.90% | n/a | -27.01% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.61 | 49.87M | 3.21% | n/a | 1.95% |
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.32 | 49.23M | -2.74% | n/a | 7.83% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.87 | 47.75M | 3.89% | n/a | 6.85% |
| Acurx Pharmaceuticals Inc. Common Stock | ACXP | Biotechnology | 2.93 | 47.60M | 12.26% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.14 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 106.21 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 49.43M | 3.66B | Emerging |